To evaluate ixekizumab , an anti-interleukin-17A ( anti-IL-17A ) monoclonal antibody , in 2 populations of rheumatoid arthritis ( RA ) patients : biologics-naive patients and patients with an inadequate response to tumor necrosis factor ( TNF ) inhibitors .